Drug Landscape ›
fluticasone nasal spray ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 419
Most-reported reactions
Dyspnoea — 72 reports (17.18%) Drug Ineffective — 69 reports (16.47%) Cough — 45 reports (10.74%) Product Quality Issue — 43 reports (10.26%) Headache — 41 reports (9.79%) Nausea — 35 reports (8.35%) Asthma — 33 reports (7.88%) Fatigue — 32 reports (7.64%) Diarrhoea — 26 reports (6.21%) Dizziness — 23 reports (5.49%)
Source database →
fluticasone nasal spray in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is fluticasone nasal spray approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for fluticasone nasal spray in United States?
Organon and Co is the originator. The local marketing authorisation holder may differ — check the official source linked above.